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Drug-related behaviors in both humans and rodents are commonly thought to arise
from aberrant learning processes. Preclinical studies demonstrate that the acquisition
and expression of many drug-dependent behaviors involves the ventral tegmental area
(VTA), a midbrain structure comprised of dopamine, GABA, and glutamate neurons.
Drug experience alters the excitatory and inhibitory synaptic input onto VTA dopamine
neurons, suggesting a critical role for VTA afferents in mediating the effects of drugs. In
this review, we present evidence implicating the VTA in drug-related behaviors, highlight
the diversity of neuronal populations in the VTA, and discuss the behavioral effects of
selectively manipulating VTA afferents. Future experiments are needed to determine
which VTA afferents and what neuronal populations in the VTA mediate specific drug-de-
pendent behaviors. Further studies are also necessary for identifying the afferent-specific 
synaptic alterations onto dopamine and non-dopamine neurons in the VTA following
drug administration. The identification of neural circuits and adaptations involved with
drug-dependent behaviors can highlight potential neural targets for pharmacological and 
deep brain stimulation interventions to treat substance abuse disorders.
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iNTRODUCTiON
Illicit drug use is a significant global problem, with the United Nations Office on Drugs and Crime 
estimating that 246 million people worldwide used illicit drugs in 2013. More problematic is the high 
incidence of substance use disorders (SUDs), which in 2014 was estimated to afflict roughly 21.5 
million people in the US, corresponding to ~8% of the population (1). In addition to the personal 
impact of a SUD, there is a significant economic impact due to lost productivity, crime, and health 
care costs, which according to the US office of National Drug Policy is estimated to cost $180.8 billion 
per year in the US alone.
SUDs are now recognized to exist along a continuum where the severity of the disorder is related 
to the number of diagnostic criteria met by an individual within the past year. According to the 
DSM-V, the criteria for a SUD fall into four major symptomatic clusters: impaired control (i.e., use 
more than intended), social impairment (i.e., substance use at the expense of personal relationships 
and impaired job performance), risky behavior (i.e., use despite known adverse consequences), 
and pharmacological effects (i.e., tolerance and withdrawal). One of the most daunting aspects 
in treating SUDs is the high incidence of relapse, which occurs in ~40–60% of individuals (2). In 
drug users, exposure to drug-paired cues elicits craving that in turn can promote the possibility 
of a relapsing episode (3). Weakening the relationship between drugs and associated cues holds 
promise as a non-pharmacological method for treating SUDs (4). However, our understanding of 
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the specific neural circuits and neural adaptations responsible 
for drug-related behaviors is incomplete.
RODeNT MODeLS OF DRUG-DePeNDeNT 
BeHAviORS
Rodent model systems are commonly employed to examine the 
effects of abused drugs on behavior. In this review, we will con-
centrate on psychostimulants and opiates, as extensive laboratory 
research has focused on these drug categories. The non-contingent 
administration of psychostimulants or opiates increases locomo-
tor activity in rodents (5). Repeated non-contingent drug injec-
tions can lead to a progressive and long-lasting increase in this 
drug-induced locomotor activity, a phenomenon referred to as 
behavioral sensitization (5). A single injection of cocaine at high 
doses is also capable of eliciting sensitization (6, 7). Furthermore, 
even when no drug is administered, locomotor activity is elevated 
in the same context where animals received a single drug injec-
tion on the preceding day (8). These results illustrate that the 
association between a drug and the context where the drug is 
experienced is rapidly learned following a single exposure.
Drug-paired cues exert a powerful influence over behavioral 
actions in individuals with a SUD (3). The development of an 
association between drugs and cues can be examined in humans 
in the laboratory (9, 10), as well as in rodents by utilizing a 
conditioned place preference (CPP) behavioral paradigm (11). 
This rodent assay involves repeated non-contingent drug injec-
tions in one chamber and control injections in an adjacent, but 
contextually distinct chamber. The relative preference between 
the drug-paired and control contexts is subsequently assessed in 
a test session where the rodent can freely access both chambers 
in a drug-free state (11). The CPP training procedure can include 
an extinction phase and a reactivation test (12, 13), which models 
drug abstention and relapse observed in humans suffering from 
a SUD. While CPP paradigms examine contextual learning 
involving reinforcing outcomes, conditioned place aversion 
(CPA) assays examine learning involving aversive outcomes. In 
particular, CPA paradigms are commonly utilized to study the 
negative affective state following drug withdrawal (14, 15).
Behavioral sensitization and CPP paradigms are relatively easy 
to implement, but they require experimenter administered drug 
injections. Rodents can be readily trained to self-administer drugs 
via an intravenous catheter. A number of drug self-administration 
assays have been developed to model the behavioral symptoms 
observed in humans with a SUD. For example, rodents with 
limited access (1 h) to drugs in daily self-administration sessions 
maintain stable drug intake. However, rodents with extended 
access (6 h) to drugs increase their intake over multiple training 
sessions, similar to the escalated drug consumption that can be 
observed in individuals diagnosed with a SUD (16–18). Just as 
drug use does not necessarily lead to a SUD, not every rodent who 
self-administers drugs will develop an addiction-related pheno-
type. When rodents are extensively trained to self-administer 
drugs (~3 months), a subset of rats exhibit characteristics found 
in humans with SUDs, such as persistent drug seeking in the 
absence of reinforcement, exerting greater effort to obtain a drug 
infusion, and seeking drugs despite aversive consequences (19). 
Rodents trained to self-administer drugs are also used to model 
relapse. Relapse in humans is often precipitated by three major 
factors: taking the drug, exposure to cues previously associated 
with the drug, or experiencing a stressful life-event (20–22). 
These same triggers (drug intake, exposure to drug-related cues, 
or stress) can reinstate drug-seeking behaviors in rodent drug 
self-administration models as well (23).
Just as with humans with a SUD, drug-dependent behaviors in 
rodents involve a component of learning, whether it is contextual 
(behavioral sensitization, CPP, CPA, and cue-induced reinstate-
ment) or operant (drug self-administration). While numerous 
brain regions are involved with mediating learning and drug-
related behaviors, we will focus on the ventral tegmental area 
(VTA) in this review. We will also discuss the major inputs to 
the VTA, how these inputs influence VTA neuron activity, and 
present recent findings on how these VTA afferents are involved 
with drug-dependent behaviors.
vTA iNvOLveMeNT iN DRUG-
DePeNDeNT BeHAviORS
The dopamine neurons arising from the VTA that project to 
the nucleus accumbens (NAc) are involved with mediating the 
reinforcing actions of abused substances (24–26). While abused 
drugs increase dopamine levels in the NAc (27, 28), many 
non-habit forming drugs do not affect dopamine overflow (27). 
Psychostimulants affect dopamine levels primarily by altering 
dopamine clearance from the extracellular space (29, 30), whereas 
opiates indirectly elevate dopamine transmission by suppressing 
inhibitory input onto dopamine neurons (31–33).
The neural circuitry mediating any behavior is complex, 
though extensive research over the past few decades illustrates that 
the VTA is critically involved with both rewarding and aversive 
drug-dependent behaviors. For example, the VTA is required for 
behavioral sensitization induced by amphetamine or mu-opioid 
receptor agonists, though evidence for the involvement of the 
VTA in cocaine behavioral sensitization is mixed (5). The VTA 
is also involved with CPP for both psychostimulants and opiates 
(34–39), and with CPA elicited by kappa opioid receptor activation 
(15). The VTA is also necessary for stress-, cue-, and drug-primed 
reinstatement in rodents self-administering cocaine (23, 40–42) 
or heroin (43–45). While VTA-dependent behaviors are often 
mediated by dopamine neurons, increasing evidence illustrates 
the involvement of non-dopamine VTA neurons in regulating 
behavioral outcomes.
DiveRSe NeURONAL POPULATiONS 
wiTHiN THe vTA
The VTA along with the neighboring substantia nigra pars 
compacta are the primary dopamine producing nuclei in the 
brain (46). Early electrophysiological recordings indicated that 
the VTA was comprised of two distinct neuronal populations, 
presumed to be dopamine neurons and local GABA interneurons 
(31, 47). However, a subset of VTA neurons exhibited a unique 
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electrophysiological response to serotonin and opioid receptor 
agonists, providing evidence for the existence of an additional 
neuronal population in the VTA (48). Accumulating evidence 
over the past decade has highlighted the complexity of the VTA 
both in regards to neuronal composition and projection targets.
Dopamine neurons comprise the largest neuronal population 
within the VTA, as tyrosine hydroxylase (TH), the rate-limiting 
enzyme for dopamine synthesis, is found in ~60% of VTA neurons 
(46, 49). VTA dopamine neurons typically innervate only a single 
target region, with different populations projecting to numerous 
brain nuclei, including the NAc, dorsal striatum, cortex, amygdala, 
globus pallidus, and lateral habenula (LHb) (46, 50, 51). However, 
recent evidence indicates that dopamine neurons projecting to 
the medial NAc also send collaterals outside of the striatum (50). 
Traditionally, dopamine neurons have also been identified based 
upon electrophysiological properties, including the presence of 
a long triphasic action potential, a low baseline firing rate, burst 
firing, and the presence of the Ih current (52, 53). However, 
action potential duration may not be sufficient to identify the 
neurotransmitter content of VTA neurons (49, 54). Additionally, 
many neurons within the medial aspects of the VTA have Ih but 
do not contain TH. While action potential duration and Ih are not 
always indicative of dopamine content, these electrophysiological 
properties can be related to where VTA neurons project (55–57).
The second largest neuronal population in the VTA consists 
of GABA neurons (~25%) that are commonly identified by the 
presence of glutamic acid decarboxylase (GAD) (58, 59). While 
initially thought to function primarily as local interneurons (31), 
VTA GABA neurons directly influence the activity of VTA dopa-
mine neurons (60, 61) and also project to the ventral pallidum 
(VP), lateral hypothalamus (LH), and LHb, with smaller projec-
tions to the amygdala, prefrontal cortex (PFC), and NAc (62–64). 
Recently, dopamine neurons were identified as an additional 
source of GABA in the VTA, as these neurons can synthesize 
GABA through an aldehyde dehydrogenase-mediated pathway 
(65). VTA and substantia nigra dopamine neurons package 
GABA into vesicles through the vesicular transporter for dopa-
mine, indicating that GABA can be coreleased with dopamine 
to elicit electrophysiological effects on medium spiny neurons in 
both the NAc and dorsal striatum (66, 67).
In addition to dopamine and GABA neurons, a small percent-
age of VTA neurons contain vesicular glutamate transporter 2 
(VGluT2), a marker for glutamate neurons. These neurons pre-
dominately reside in the medial aspects of the VTA and project 
to the ventral striatum, PFC, VP, amygdala, and LHb, as well as 
synapse onto local dopamine neurons (57, 64, 68–72). A subset 
of the VGluT2 positive neurons in the VTA also express TH and 
can project to the PFC and ventral striatum (70). These neurons 
release both dopamine and glutamate (73–77) though they are 
not typically released at the same site or from the same synaptic 
vesicles (78). While the VTA was thought to be comprised solely 
of dopamine and GABA neurons, recent studies illustrate that 
the VTA is comprised of dopamine neurons that can corelease 
GABA, dopamine neurons that corelease glutamate, GABA 
neurons, and glutamate neurons.
Optogenetic modulation of VTA neurons can elicit either 
appetitive or aversive behavioral outcomes depending upon the 
neuronal population that is targeted. Activation of dopamine 
neurons is acutely reinforcing and sufficient for establishing a 
CPP, whereas silencing dopamine neurons is aversive and elicits 
a CPA (60, 79, 80). Stimulating VTA dopamine neurons also 
enhances reinforcing behaviors in operant tasks (81–84). In 
contrast, selective activation of VTA GABA neurons is aversive, 
elicits a CPA, and reduces reward consumption by inhibiting the 
activity of local VTA dopamine neurons (60, 61). Interestingly, 
activating VTA GABA neurons that synapse onto cholinergic 
interneurons in the NAc enhances the discrimination between 
neutral and aversive stimuli (63). Optogenetic activation of 
VGluT2-containing neurons in the VTA is also sufficient for 
establishing CPP, an effect that is mediated by activating local 
VTA dopamine neurons (72). Collectively, these studies suggest 
that VTA-mediated behavioral effects, including drug-dependent 
behaviors, likely involve a complex interplay between the distinct 
neuronal populations in the VTA.
AFFeReNT ReGULATiON OF THe vTA
The VTA is innervated by a diverse array of inputs, many of 
which are interconnected. Large afferents to the VTA include 
the rostromedial tegmental nucleus (RMTg), VP, bed nucleus of 
the stria terminalis (BNST), LH, pedunculopontine tegmental 
nucleus (PPT), laterodorsal tegmental nucleus (LDT), dorsal 
raphe nucleus (DR), NAc, PFC, and amygdala (50, 85–87). While 
VTA dopamine and GABA neurons are innervated by many of 
the same brain regions (50), little is known about the inputs to 
VGluT2 positive neurons in the VTA. Below, we will discuss how 
notable inputs to the VTA can influence the activity of VTA neu-
rons, how these inputs influence VTA-dependent behaviors, and 
recent findings on VTA afferents involved with drug-dependent 
behaviors.
Rostromedial Tegmental Nucleus
The RMTg (also referred to as the tail of the VTA) is a nucleus 
comprised of GABA neurons that function as an inhibitory relay 
between the LHb and the VTA (86, 88–92). Lesions of the RMTg 
demonstrate a critical role for this brain region in modulating 
aversive behaviors (86). Additionally, neurons in the RMTg are 
activated by aversive stimuli and inhibited by rewards (86). The 
RMTg heavily influences the firing of VTA neurons, as RMTg 
inactivation increases dopamine neuron firing (93), whereas 
stimulating the RMTg attenuates dopamine neuron firing (93–95).
The RMTg is increasingly recognized as an important nucleus 
in mediating the effects of abused drugs. The reinforcing effect 
of opiates was originally thought to arise from activation of 
mu-opioid receptors on VTA GABA interneurons (31), though 
accumulating evidence suggests the major target of opiates is 
instead the RMTg afferents to the VTA (33, 96, 97). The admin-
istration of morphine decreases RMTg cell firing, which reduces 
the inhibition onto VTA dopamine neurons, resulting in elevated 
dopamine neuron firing (94–96). Indeed, selective activation of 
mu-opioid receptors in RMTg neurons projecting to the VTA is 
sufficient for eliciting a real-time place preference (98). Following 
opiate withdrawal, inhibiting RMTg neurons no longer elevates 
VTA dopamine neuron firing. This inability of the RMTg to 
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disinhibit dopamine neurons is mediated in part by an alteration 
in VTA glutamatergic tone (93). While the RMTg projection to 
the VTA mediates the acute reinforcing effects of opiates (33, 
96, 98), additional VTA afferent pathways are involved with 
dopamine neuron tolerance to opiates following withdrawal (93).
Psychostimulants also influence the activity of RMTg neurons 
(94). The non-contingent administration of cocaine elevates the 
levels of Fos, a transcription factor associated with increased 
neuronal activity, in RMTg neurons (99, 100). Interestingly, Fos 
levels in RMTg neurons projecting to the VTA are elevated fol-
lowing extinction in rats self-administering cocaine (101). The 
RMTg is also necessary for cocaine-related aversive behaviors 
that are observed once the rewarding effect of cocaine dissipates 
(102). Further experimentation is needed to validate whether the 
RMTg projection to the VTA is involved with both aversive and 
reinforcing behaviors elicited by cocaine.
ventral Pallidum
The VP is involved in processing rewarding stimuli and motivated 
behavior (103). GABA neurons in the VP provide a large source 
of inhibitory input to the VTA (87, 104). Activating VP neuron 
terminals elicits inhibitory GABA currents in both dopamine 
and non-dopamine VTA neurons (105). The functional effect 
of inactivating the VP results in an increase in the population 
activity in putative dopamine neurons (106) though the effect 
on non-dopamine VTA neurons is unknown. Numerous lines 
of evidence implicate the VP in drug-dependent behaviors. VP 
neurons projecting onto dopamine and non-dopamine neurons 
are acutely inhibited by opiates (105). Additionally, VP lesions or 
pharmacological manipulations in the VP can block morphine-
induced sensitization (107, 108), drug-induced CPP (35, 109, 
110), self-administration (111), and reinstatement (40, 41, 112). 
VP neurons projecting to the VTA are Fos activated following 
cue-induced reinstatement for cocaine (101) and silencing these 
neurons is sufficient for blocking cue-induced reinstatement 
(113). While VP neurons project to both dopamine and non-
dopamine neurons in the VTA (105), it is unclear what neuronal 
population(s) in the VTA are influenced by the VP inputs during 
drug-dependent behaviors.
Bed Nucleus of the Stria Terminalis
The BNST is involved in mediating fear and anxiety (114–120) 
and is considered to be a relay nucleus between stress and reward 
pathways (121, 122). The neuronal composition of the BNST is 
diverse, with efferent populations of GABA and glutamate neu-
rons along with local GABA and cholinergic interneurons (122, 
123). BNST neurons also express an assortment of neuropeptides 
including neuropeptide Y, corticotropin-releasing factor, enkepha-
lin, dynorphin, and substance P (124). Electrical stimulation of 
the BNST exerts an excitatory influence on midbrain dopamine 
neurons (122, 125, 126) and elevates dopamine release in the NAc 
(127). Recent studies suggest that this excitatory effect on dopa-
mine neurons is predominately mediated through GABA BNST 
neurons disinhibiting VTA GABA neurons, resulting in anxiolytic 
and rewarding behavioral outcomes (128–130). Interesting, glu-
tamate neurons in the BNST also innervate VTA GABA neurons, 
and activation of these neurons elicits aversive and anxiogenic 
behaviors (129). Within the context of drug-dependent behaviors, 
local pharmacological manipulations illustrate a critical role of 
the BNST in the stress-induced reinstatement of drug seeking (41, 
131, 132). Furthermore, recent studies implicate the BNST–VTA 
pathway in the locomotor-activating effects of cocaine (133) and 
in the expression of cocaine CPP (134), though the involvement 
of this pathway in other drug-dependent behaviors has not yet 
been explored.
Lateral Hypothalamus
The LH is critical for the expression of motivated behaviors 
including feeding and drug seeking (135). The LH provides both 
glutamate and GABA inputs to the VTA (85, 136). In addition, 
LH neurons projecting to the VTA also contain neuropeptides 
such as neurotensin and orexin/hypocretin (137, 138). Electrical 
stimulation of the LH increases the activity of putative dopamine 
neurons and inhibits the activity of putative GABA neurons 
in the VTA (139). Many lines of evidence demonstrate that 
activation of this LH–VTA pathway is reinforcing. Rodents will 
readily self-stimulate for electrical activation of the LH, but this 
behavioral effect is inhibited by dopamine receptor antagonism 
(140) or inactivation of the VTA (141). Furthermore, optogenetic 
activation of LH inputs to the VTA also supports self-stimulation 
through a neurotensin-dependent mechanism (142).
Accumulating evidence over the past decade highlights 
the importance of orexin-containing neurons in feeding, 
the sleep/wake cycle, and drug-dependent behaviors (143). 
Orexin-producing neurons are exclusively localized within the 
hypothalamus and project widely throughout the brain (144), 
though it is the projection to the VTA that is heavily involved 
with drug-dependent behaviors. Intra-VTA injections of orexin 
receptor antagonists attenuate morphine CPP (145, 146), which 
is consistent with the reduced morphine dependence observed in 
orexin-deficient mice (147). Conversely, intra-VTA administra-
tion of orexin reinstates morphine CPP (12). Orexin antagonists 
targeting the VTA also diminish behavioral sensitization to 
cocaine (148), cocaine self-administration (149), and cue-induced 
reinstatement (150). Interestingly, orexin neurons in the LH also 
contain dynorphin, which inhibits the activity of VTA dopamine 
neurons. A recent study suggests that orexin in the VTA facilitates 
drug-related behaviors in part through attenuating the effects of 
dynorphin (149). Although the orexin-containing neurons in the 
LH have received considerable attention in the context of addic-
tion, additional neuronal populations in the LH–VTA pathway 
are also likely involved in drug-dependent behaviors, as the non-
orexin-producing neurons in the LH are Fos activated following 
cue-induced reinstatement (101).
Laterodorsal Tegmental Nucleus and 
Pedunculopontine Tegmental Nucleus
The LDT and PPT are involved in modulating arousal and reward-
driven behaviors (92, 151–154). These nuclei are comprised of 
distinct populations of acetylcholine, GABA, and glutamate 
neurons that project to the midbrain dopamine system (155, 
156). Anatomical studies indicate that the VTA primarily receives 
input from the LDT (87, 155, 157). In vivo electrophysiological 
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experiments illustrate that electrical stimulation of the LDT 
elicits burst firing in putative VTA dopamine neurons (158). 
Selective activation of LDT inputs to the VTA evokes excitatory 
currents in VTA dopamine neurons projecting to the lateral NAc 
(92). Stimulating this LDT–VTA pathway in vivo elicits CPP and 
reinforces operant responding (92, 154). Increasing evidence 
indicates that the LDT is also involved in drug-dependent 
behaviors. Specifically, local pharmacological manipulations 
demonstrate the LDT is critical for the acquisition and expression 
of cocaine CPP (159), as well as with cocaine-primed reinstate-
ment of drug seeking (160). Interestingly, the cholinergic neurons 
of the LDT are involved with the behavioral responsiveness to 
cocaine-paired cues (161). Further studies are needed to ascertain 
whether drug-dependent behaviors also involve the GABA and 
glutamate projections from the LDT to the VTA.
Whereas the VTA is preferentially innervated by the LDT, the 
PPT primarily targets the substantia nigra (87, 155). Although 
the anatomical evidence indicates there is a small PPT projec-
tion to the VTA (87, 155), electrophysiological studies in vivo 
and in vitro suggest a functional relationship exists between the 
PPT and VTA (106, 162, 163). The discrepancy between the 
anatomical and electrophysiological studies is unclear, though 
proposed explanations include the possibility that a single PPT 
neuron innervates numerous VTA neurons or that electrical 
stimulation excites fibers of passage or nearby regions, such as 
the LDT (87). Regardless, electrical stimulations targeting the 
PPT increases burst firing of putative VTA dopamine neurons 
(106), while PPT inactivation reduces dopamine neuron firing 
to salient stimuli (162). The PPT is also implicated in drug-
dependent behaviors, as lesions attenuate amphetamine- and 
morphine-induced locomotor activity (164), and PPT inactiva-
tion reduces cocaine-primed reinstatement of drug seeking 
(160). PPT lesions reduce both heroin self-administration and 
morphine CPP (165, 166). However, PPT cholinergic neurons 
are not involved with cocaine self-administration, heroin self-
administration, cocaine CPP, and heroin CPP (167), suggesting 
the involvement of PPT glutamate and/or GABA neurons in 
these drug-related behaviors.
Dorsal Raphe
The DR is the primary source of serotonin in the brain, but also 
contains glutamate (85), GABA (168), and dopamine neurons 
(169). While the DR is often studied within the context of 
controlling affective state (170), it is also involved in reinforcing 
instrumental behavior (171). Serotonin exerts a variety of elec-
trophysiological responses in VTA neurons. The predominant 
in  vitro response in putative dopamine neurons is excitatory, 
though a small proportion of dopamine neurons are inhibited 
by serotonin (172). In contrast, equal numbers of putative GABA 
neurons are excited and inhibited by serotonin (172). The net 
effect of these electrophysiological responses appears to be excita-
tory, as in  vivo intra-VTA administration of serotonin elevates 
dopamine levels in the NAc (173).
Serotonin influences drug-related behaviors (174), which 
could involve the DR serotonin neurons projecting to the VTA. 
However, the DR projection to the VTA is primarily comprised 
of glutamate neurons that predominantly innervate dopamine 
neurons (85, 87, 175). Activation of DR glutamate neurons 
evokes excitatory currents in VTA dopamine neurons and 
elicits dopamine release in the NAc (175). Selective activation 
of the non-serotonergic DR–VTA pathway reinforces instru-
mental behavior and is sufficient for eliciting CPP (175, 176). 
In contrast, activation of serotonergic DR neurons projecting 
to the VTA is only weakly reinforcing (176). These anatomical 
and behavioral findings suggest that the VTA is likely not a 
primary locus where serotonin acts to influence drug-related 
behaviors. Instead, the non-serotonergic DR neurons project-
ing to the VTA are well positioned to mediate drug-dependent 
behaviors, though this has not yet been experimentally 
examined.
Nucleus Accumbens
GABA neurons in the NAc project to the VTA and are thought 
to mediate a “long-loop” inhibitory feedback to regulate dopa-
mine neuron activity (177). Mu-opioid receptor agonists acutely 
inhibit the GABA afferents from the NAc to the VTA (33, 178). 
The inhibitory transmission from the NAc inputs onto VTA 
GABA neurons is enhanced following repeated injections of 
cocaine, which in turn disinhibits VTA dopamine neurons (179). 
In addition to being influenced by opiates and psychostimulants, 
the NAc afferents to the VTA are Fos activated during cocaine 
cue-induced reinstatement (101). While these results suggest 
the NAc–VTA pathway is involved in drug-related behaviors, 
no experiments to date have examined the behavioral effect of 
selectively perturbing this pathway.
Prefrontal Cortex
The medial PFC mediates a variety of cognitive functions (180), 
is involved in the reinstatement of drug-seeking behavior (23), 
and exhibits Fos activation following an acute administration 
of amphetamine (181). The VTA receives a dense glutamate 
projection from the medial PFC (85), with pyramidal neurons 
synapsing onto both dopamine and non-dopamine VTA 
neurons (62, 182). Electrically stimulating the PFC can either 
inhibit or excite putative dopamine neurons within the VTA 
(183, 184). Whereas single pulse or low frequency PFC stimula-
tion inhibits a majority of VTA dopamine neurons (183–185), 
burst stimulation of the PFC excites >90% of VTA dopamine 
neurons (184). The mechanism behind the dopamine neuron 
excitation is unclear, as VTA dopamine neurons receive sparse 
input from the PFC (87, 186), with <15% of VTA dopamine 
neurons being excited by selective activation of medial PFC 
inputs (50). These findings collectively suggest the medial PFC 
preferentially targets VTA GABA neurons, though the relevance 
of this PFC-VTA pathway in drug-dependent behaviors has not 
been examined.
Amygdala
The amygdala is an interconnected group of nuclei involved with 
attributing emotional value to cues (187, 188). The VTA receives 
amygdala input arising from the central nucleus of the amygdala 
(CeA) subdivision (87, 189). The CeA contains predominantly 
GABA neurons and is involved with fear conditioning (187, 188, 
190), as well as with mediating the general motivational influence 
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of rewarding cues (191, 192). In the context of drug-dependent 
behaviors, the CeA facilitates the expression of conditioned 
responding (193) and is also involved with mediating stress-
induced reinstatement of drug-seeking behavior (194, 195). 
While the CeA projects to the VTA, it is currently unknown how 
this pathway influences VTA neuron activity and whether it is 
crucial for drug-dependent behaviors.
DRUG-iNDUCeD SYNAPTiC PLASTiCiTY 
ON vTA NeURONS
The transition of an individual from drug naive or casual drug 
user to SUDs involves changes in the function of specific neural 
circuits (196). Given the importance of the VTA in drug-related 
behaviors, the synaptic adaptations in VTA dopamine neurons 
have been extensively studied and reviewed elsewhere (197–201). 
Numerous studies from a variety of laboratories have consist-
ently demonstrated an increase in excitatory synaptic strength 
onto VTA dopamine neurons after in vivo exposure to abused 
drugs (202–208). Many of these studies examined the effect of 
drugs on the ratio of the AMPA receptor current to the NMDA 
receptor current (AMPA/NMDA) in VTA neurons, which allows 
for comparing the excitatory synaptic strength between different 
groups of animals (i.e., drug treated vs. control). In vivo exposure 
to drugs of abuse increases the AMPA/NMDA (202–204, 206, 
207), which is mediated by insertion of calcium-permeable 
AMPA receptors and removal of NMDA receptors in VTA 
dopamine neurons (205, 208).
In addition to the excitatory synaptic alterations in VTA dopa-
mine neurons, in vivo exposure to drugs also modulates inhibi-
tory synaptic inputs to the VTA. For example, repeated injections 
of cocaine potentiate the NAc inhibitory input to VTA GABA 
neurons, which results in a disinhibition of dopamine neurons 
(179). This disinhibition also facilitates the ability to elicit excita-
tory long-term potentiation (LTP) in VTA dopamine neurons 
(209). VTA dopamine neurons are also capable of undergoing 
inhibitory LTP. Furthermore, this inhibitory LTP is blocked fol-
lowing an in  vivo exposure to opiates (210, 211). A myriad of 
drug-induced synaptic alterations have been reported, though it 
is important to note that the full complement of electrophysiologi-
cal changes and the duration of these alterations in VTA neurons 
depends upon the drug, the drug dose, and the manner the drug 
is administered (202–204, 206, 207, 212). Few studies to date 
have examined whether these drug-induced synaptic changes 
occur in an afferent-specific manner (179, 212). Indeed, in vivo 
exposure to different classes of abused drugs results in alterations 
in distinct excitatory inputs to VTA dopamine neurons (212). 
Although much has been learned regarding synaptic alterations 
in the VTA following non-contingent injections of abused drugs, 
additional studies are needed to ascertain the similarities and 
differences in the synaptic changes evoked by different classes 
of abused drugs (psychostimulants, opiates, alcohol, nicotine, 
etc.). Furthermore, electrophysiological studies are also needed 
to identify which VTA afferents and what VTA neuronal popula-
tions undergo synaptic alterations following contingent drug 
self-administration.
CONCLUSiON
The high incidence of relapse illustrates the need for identify-
ing new therapeutic approaches for the treatment of SUDs. 
The treatment of opioid dependence is complicated by the 
severe withdrawal symptoms experienced by individuals when 
ceasing drug intake. The current treatment options for opioid 
SUDs typically focus on opioid maintenance with methadone 
or buprenorphine and detoxification with alpha-2 receptor 
agonists. However, these current treatment options often 
result in relapse (213). Currently there is no FDA-approved 
pharmacotherapy for the treatment of cocaine SUDs, though 
N-acetylcysteine is a promising and well-tolerated drug that 
reduces cocaine-seeking in rodents and craving in cocaine-
dependent humans (214–217). Over the past decade, research 
on effective pharmacological treatments for alcohol SUDs 
has identified many potential targets, including opioid recep-
tors (218), dopamine receptors (219), glutamate receptors 
(220), GABA receptors (221), and adrenergic receptors (222). 
Preclinical research highlighted the cannabinoid system as a 
promising target for multiple SUDs (223, 224). However, a car-
diovascular clinical study examining the efficacy of rimanobant, 
a cannabinoid receptor antagonist, elicited severed negative 
neuropsychiatric effects (225) and has dampened enthusiasm 
for targeting the endocannabinoid system for treating SUDs. 
Unfortunately, no single pharmacotherapy currently exists for 
treating a broad spectrum of SUDs.
An alternative therapeutic direction for the treatment of 
SUDs involves the use of deep brain stimulation (DBS), which 
commonly has been utilized for the treatment of movement 
disorders. In preclinical studies, DBS targeting the NAc reduced 
cocaine behavioral sensitization (226), morphine CPP (227), 
reinstatement  of heroin-seeking (228), and reinstatement of 
cocaine-seeking (229–231). Additionally, DBS targeting the LHb 
reduces cocaine self-administration and the reinstatement of 
cocaine-seeking (232). Consistent with the rodent DBS experi-
ments, clinical studies indicate a complete remission or prolonged 
cessation of heroin use after DBS in the NAc in humans (233, 
234). A considerable drawback of implementing DBS in humans 
is the invasive nature of implanting the probe. However, a couple 
of recent reports illustrate that non-invasive transcranial mag-
netic stimulation of the PFC is effective at reducing drug use and 
craving (235, 236). While there are promising new therapeutic 
approaches for treating SUDs, the ultimate goal for any interven-
tion is to be effective and as specific as possible to limit side effects. 
Thus, additional basic science research is needed for identifying 
the specific neural circuits and adaptations responsible for the 
development of drug-dependent behaviors.
The implementation of optogenetic and chemogenetic 
approaches in behavioral experiments has validated and identi-
fied specific neural circuits that mediate a range of appetitive 
and aversive behaviors. Many of these studies manipulated brain 
regions implicated in SUDs (237), though relatively few have 
modulated neural circuits within the context of drug-dependent 
behaviors (98, 113, 133). While activity within the VTA is cen-
tral to numerous drug-dependent behaviors, many questions 
remain. Future experiments are needed to (i) determine which 
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VTA afferents and what neuronal populations in the VTA medi-
ate a particular drug-dependent behavior and (ii) elucidate the 
associated afferent-specific synaptic changes on both dopamine 
and non-dopamine neurons within the VTA. Identifying the 
neural circuits and adaptations responsible for drug-dependent 
behaviors in rodents can highlight specific neural circuits for 
targeted pharmacological and DBS therapeutic interventions to 
treat humans suffering from a SUD.
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